MedTrace Logo

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

NCT05984927 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-01-20

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).

Conditions

  • Age-Related Macular Degeneration

Interventions

GENETIC

NG101 AAV gene therapy

Sub retinal injection of NG101 (a non-replicating adeno-associated virus serotype 8 (AAV8) vector

Sponsors & Collaborators

  • ORA, Inc.

    collaborator INDUSTRY

  • Elisigen, Inc.

    lead INDUSTRY

Principal Investigators

  • Christopher D Riemann, MD · Neuracle Genetics, Inc. Medical Director

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-08
Primary Completion
2026-01-31
Completion
2030-01-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05984927 on ClinicalTrials.gov